Updates are available Correction dated 2022-02-15
Click to view Correction: https://doi.org/10.1007/s00408-022-00516-3
-
Authors
Todd, Jamie L. https://orcid.org/0000-0003-4247-3693
Neely, Megan L.
Overton, Robert
Mulder, Hillary
Roman, Jesse
Lasky, Joseph A.
de Andrade, Joao A.
Gulati, Mridu
Huang, Howard
Leonard, Thomas B.
Hesslinger, Christian
Noth, Imre
Belperio, John A.
Flaherty, Kevin R.
Palmer, Scott M.
,
-
Funding
Funding for this research was provided by:
the ipf-pro™ registry is funded by boehringer ingelheim pharmaceuticals, inc. and coordinated by the duke clinical research institute.
- License Information
-
More Information
Article History
Received: 28 July 2021
Accepted: 13 December 2021
First Online: 23 January 2022
Change Date: 15 February 2022
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1007/s00408-022-00516-3
Declarations
:
: The authors have reported to Lung the following conflicts of interest: JLT, MLN, RO, HM and SMP are employees of the Duke Clinical Research Institute, which was funded by Boehringer Ingelheim Pharmaceuticals, Inc to conduct this research. JR reports grants and personal fees from Boehringer Ingelheim and grants from Genentech, Galapagos, Syneos Health, Bellerophon Therapeutics, FibroGen, and the National Institutes of Health. JAL reports personal fees from Biogen, Boehringer Ingelheim, Galecto, Roche/Genentech and Veracyte. JAdA reports personal fees from Boehringer Ingelheim. MG reports personal fees, non-financial support, and other support from the France Foundation; grants, non-financial support and other support from Boehringer Ingelheim and the Pulmonary Fibrosis Foundation; and personal fees from Genentech. HH is on a speaker panel for Boehringer Ingelheim. IN reports personal fees from Boehringer Ingelheim, Genentech, and ImmuneWorks. JAB has no disclosures. KRF reports grants and personal fees from Boehringer Ingelheim and Roche/Genentech and personal fees from FibroGen, Sanofi, Genzyme, and Veracyte. TBL was an employee of Boehringer Ingelheim at the time this study was conducted. CH is an employee of Boehringer Ingelheim.
: The IPF-PRO Registry was approved by the Duke University Institutional Review Board (Pro00046131). The IPF-PRO Registry protocol was also approved by the relevant Institutional Review Boards and/or local Independent Ethics Committees prior to patient enrolment at each site.
: All patients provided informed consent.
: Not applicable.
